DIABETIC NEPHROPATHY: A NARRATIVE REVIEW FROM PATHOPHYSIOLOGY TO ITS TREATMENT
DOI:
https://doi.org/10.22159/ajpcr.2026v19i2.57291Keywords:
Diabetic nehpropathy, Diabetes mellitus, End-stage renal disease, Micro albuminuria, eGFR, RAAS, SGLT2 inhibitors, GLP-1 agonists,, Reno protectionAbstract
One of the most dangerous microvascular side effects of diabetes mellitus is diabetic nephropathy (DN), which is the primary cause of end-stage renal disease globally. Because type 2 diabetes, obesity, sedentary behavior, and metabolic syndrome are becoming more common, its occurrence is continuously rising, especially in developing countries. Persistent hyperglycemia, hemodynamic abnormalities, oxidative stress, hereditary vulnerability, and activation of inflammatory and profibrotic pathways are all part of the complex pathophysiology of diabetic kidney disease (DN), which leads to progressive renal impairment. Clinically, DN develops gradually and frequently shows no symptoms at first. Microalbuminuria is usually the first symptom, followed by persistent proteinuria, a drop in estimated glomerular filtration rate (eGFR), and finally renal failure. For prognosis and treatment, early diagnosis is crucial and depends on regular monitoring of the urine albumin-to-creatinine ratio and eGFR in addition to KDIGO staging. To distinguish non-diabetic renal diseases, renal biopsies are only performed in unusual circumstances. Strict blood pressure and glucose control, suppression of the renin-angiotensin-aldosterone system, and dietary and exercise changes are the mainstays of management. SGLT2 inhibitors, GLP-1 receptor agonists, and new anti-inflammatory and anti-fibrotic medications are examples of emerging treatments that have encouraging Reno protective benefits. Despite improvements, DN remains a significant global health and financial burden, underscoring the necessity of early screening, individualized care, and ongoing research.
Downloads
References
1. Gispen WH, Biessels GJ. Cognition and produce type II or non-insulin dependent diabetes synaptic plasticity in diabetes mellitus. Trends Mellitus Blood-glucose concentrations remained. Neurosci. 2000;23:542-9.
2. Burke JP, Williams K, Narayan KM, Leibson C, Haffner SM, Stern MP. A population perspective on diabetes prevention: Whom should we target for preventing weight gain? Diabetes Care. 2003;26:1999-2004.
3. Edem DO. Hypoglycemic effects of ethanolic extracts of alligator pear seed (Persea americana mill) in rats. Eur J Sci Res. 2009;33:669-78.
4. Baquer NZ, Gupta D, Raju J. Regulation of metabolic pathways in liver and kidney during experimental diabetes: Effects of antidiabetic compounds. Indian J Clin Biochem. 1998;13(2):63-80. doi: 10.1007/ BF02867866, PMID 23105185
5. Khuwaja AK, Khowaja LA, Cosgrove P. Cost of diabetes care in out-patient clinics of Karachi, Pakistan. BMC Health Serv Res. 2007;21:189.
6. Lyra RM. Oliveira DL, Lins D, Cavalcanti N. Prevention of type 2 diabetes mellitus. Arq Bras Endocrinol Metab. 2006;50:239-49.
7. King H, Aubert RE, Herman WH. Global burden of diabetes, 1995- 2025: Prevalence, numerical estimates, and projections. Diabetes Care. 1998;21(9):1414-31. doi: 10.2337/diacare.21.9.1414, PMID 9727886
8. Tkachenko O, Schrier RW. Blood control in diabetic nephropathy. J Nephrol Ther. 2014;4:148.
9. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: Estimates for the year 2000 and projections for 2030. Diabetes Care. 2004;27(5):1047-53. doi: 10.2337/diacare.27.5.1047, PMID 15111519
10. Ibrahim R. Diabetes mellitus type II: Review of oral treatment options. Int J Pharm Pharm Sci. 2010;2(1):20-30. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature. 2001;414:813-20.
11. Maezawa Y, Takemoto M, Yokote K. Cell biology of diabetic nephropathy: Roles of endothelial cells, tubulointerstitial cells and podocytes. J Diabetes Investig. 2014;6:3-15.
12. Dhyani S, Butola M, Sautha V, Jakhmola V. Recent advances in treatment approaches for diabetes mellitus and related complications: A review. Int J Appl Pharm. 2025;17(2):12-30.
13. Kimmelstiel P, Wilson C. Intercapillary lesions in the glomeruli of the kidney. Am J Pathol. 1936;12(1):83-98.7.
14. Sumiyoshi K, Kawata C, Shikata K, Makino H. Influencing factors for dietary behaviors of patients with diabetic nephropathy. Acta Med Okayama. 2010;64:39-47.
15. International Diabetes Federation. IDF Diabetes Atlas. 10th ed. Update Brussels: International Diabetes Federation; 2024.
16. Sun H, Saeedi P, Karuranga S, Pinkepank M, Ogurtsova K, Duncan BB, et al. IDF diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res Clin Pract. 2022;183:109119.
17. Gross JL, De Azevedo MJ, Silveiro SP, Canani LH, Caramori ML, Zelmanovitz T. Diabetic nephropathy: Diagnosis, prevention, and treatment. Diabetes Care. 2005;28(1):164-76. doi: 10.2337/diacare.28.1.164, PMID 15616252
18. Zheng Y, Ley SH, Hu FB. Global aetiology and epidemiology of type 2 diabetes mellitus and its complications. Nat Rev Endocrinol. 2018;14(2):88-98. doi: 10.1038/nrendo.2017.151, PMID 29219149
19. Collins AJ, Foley RN, Chavers B, Gilbertson D, Herzog C, Ishani A, et al. US renal data system 2013 annual data report. Am J Kidney Dis. 2014;63(Suppl 1):A7. 20. National Kidney Foundation. KDOQI Clinical Practice Guideline for Diabetes and CKD: 2012 Update 2012;59 5 Suppl 2:S1-282.
21. Chan JC, Malik V, Jia W, Kadowaki T, Yajnik CS, Yoon KH, et al. Diabetes in Asia: Epidemiology, risk factors, and pathophysiology. JAMA. 2009;301(20):2129-40. doi: 10.1001/jama.2009.726, PMID 19470990
22. International Diabetes Federation. IDF Diabetes Atlas (Regional Report: Southeast Asia). 6th ed. Brussels: International Diabetes Federation; 2013.
23. Misra A, Ganda OP. Migration and its impact on adiposity and type 2 diabetes. Nutrition. 2007;23(9):696-708. doi: 10.1016/j. nut.2007.06.008, PMID 17679049
24. Grundy SM. Metabolic syndrome pandemic. Arterioscler Thromb Vasc Biol. 2008;28(4):629-36. doi: 10.1161/ATVBAHA.107.151092, PMID 18174459
25. Ayodele OE, Alebiosu CO, Salako BL. Diabetic nephropathy--a review of the natural history, burden, risk factors and treatment. J Natl Med Assoc. 2004;96(11):1445-54. PMID 15586648
26. Ziyadeh FN. Mediators of diabetic renal disease: The case for Tgf-beta as the major mediator. J Am Soc Nephrol. 2004;15 Suppl 1:S55-7. doi: 10.1097/01.ASN.0000093460.24823.5B, PMID 14684674
27. Kumar A, Deepak RK, Kumar S. Clinical spectrum and pathophysiological insights of diabetic nephropathy in type II diabetes mellitus. Int J Curr Pharm Rev Res. 2024;16(6):245-50.
28. Ichinose K, Kawasaki E, Eguchi K. Recent advancement of understanding pathogenesis of type 1 diabetes and potential relevance to diabetic nephropathy. Am J Nephrol. 2007;27(6):554-64. doi: 10.1159/000107758, PMID 17823503
29. Raptis AE, Viberti G. Pathogenesis of diabetic nephropathy. Exp Clin Endocrinol Diabetes. 2001 109 Suppl 2:S424-37.
30. Singh DK, Winocour P, Farrington K. Mechanisms of disease: The hypoxic tubular hypothesis of diabetic nephropathy. Nat Clin Pract Nephrol. 2008;4:216-26.
31. Ziyadeh FN, Wolf G. Pathogenesis of the podocytopathy and proteinuria in diabetic glomerulopathy. Curr Diabetes Rev. 2008;4(1):39-45. doi: 10.2174/157339908783502370, PMID 18220694
32. Wolf G, Ziyadeh FN. Molecular mechanisms of diabetic renal hypertrophy. Kidney Int. 1999;56:393-405.
33. Wolf G, Ziyadeh FN. Cellular and molecular mechanisms of proteinuria in diabetic nephropathy. Nephron Physiol. 2007;106(2):26-31. doi: 10.1159/000101797, PMID 17570945
34. Hilgers KF, Veelken R. Type 2 diabetic nephropathy: Never too early to treat? J Am Soc Nephrol. 2005;16(3):574-5. doi: 10.1681/ ASN.2005010083, PMID 15703269
35. Harris RD, Steffes MW, Bilous RW, Sutherland DE, Mauer SM. Global glomerular sclerosis and glomerular arteriolar hyalinosis in insulin dependent diabetes. Kidney Int. 1991;40(1):107-14. doi: 10.1038/ ki.1991.187, PMID 1921145
36. Heilig CW, Concepcion LA, Riser BL, Freytag SO, Zhu M, Cortes P. Overexpression of glucose transporters in rat mesangial cells cultured in a normal glucose milieu mimics the diabetic phenotype. J Clin Invest. 1995;96(4):1802-14. doi: 10.1172/JCI118226, PMID 7560072
37. Chen ZJ, Yang YB, Huang SM. Expression of VEGF in kidney of diabetic rats. Sichuan Da Xue Xue Bao Yi Xue Ban. 2007;38(4):633-6.
38. Wolf G, Chen S, Ziyadeh FN. From the periphery of the glomerular capillary wall toward the center of disease: Podocyte injury comes of age in diabetic nephropathy. Diabetes. 2005;54(6):1626-34. doi: 10.2337/diabetes.54.6.1626, PMID 15919782
39. Friedman EA. Advanced glycation end products in diabetic nephropathy. Nephrol Dial Transplant. 1999;14 Suppl 3:90003. doi: 10.1093/ndt/14. suppl_3.1
40. Porte D Jr., Schwartz MW. Diabetes complications: Why is glucose potentially toxic? Science. 1996;272(5262):699-700. doi: 10.1126/ science.272.5262.699, PMID 8614830
41. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature. 2001;414(6865):813-20. doi: 10.1038/414813a, PMID 11742414
42. Dharani B, Sebastian S, Nazrin S, Suba A. Preventing diabetic kidney disease: A systematic review of current pharmacological approaches. Int J Appl Pharm. 2025 Jan 7;17:68-81. doi: 10.22159/ ijap.2025v17i1.52956
43. Makita Z, Radoff S, Rayfield EJ, Yang Z, Skolnik E, Delaney V, et al. Advanced glycosylation end products in patients with diabetic nephropathy. N Engl J Med. 1991;325(12):836-42. doi: 10.1056/ NEJM199109193251202, PMID 1875967
44. Singh AK, Mo W, Dunea G, Arruda JA. Effect of glycated proteins on the matrix of glomerular epithelial cells. J Am Soc Nephrol. 1998;9: 802-10.
45. Cooper ME. Pathogenesis, prevention, and treatment of diabetic nephropathy. Lancet. 1998;352(9123):213-9. doi: 10.1016/S0140- 6736(98)01346-4, PMID 9683226
46. Yamagishi SI, Fukami K, Ueda S, Okuda S. Molecular mechanisms of diabetic nephropathy and its therapeutic intervention. Curr Drug Targets. 2007;8(8):952-9. doi: 10.2174/138945007781386884, PMID 17691932
47. Kunisaki M, Bursell SE, Umeda F, Nawata H, King GL. Normalization of diacylglycerol-protein kinase C activation by vitamin E in aorta of diabetic rats and cultured rat smooth muscle cells exposed to elevated glucose levels. Diabetes. 1994;43:1372-7.
48. Haneda M, Kikkawa R, Sugimoto T, Koya D, Araki S, Togawa M, et al. Abnormalities in protein kinase C and MAP kinase cascade in mesangial cells cultured under high glucose conditions. J Diabetes Complications. 1995;9(4):246-8. doi: 10.1016/1056-8727(95)80013-5, PMID 8573738
49. Ciuchi E, Odetti P, Prando R. Relationship between glutathione and sorbitol concentrations in erythrocytes from diabetic patients. Metabolism. 1996;45(5):611-3. doi: 10.1016/S0026-0495(96)90032-3, PMID 8622605
50. Cameron NG, Ma C, Basso M, Hohman T. Comparison of the effects of inhibitors of aldose reductase and sorbitol dehydrogenase on neurovascular function, nerve conduction and tissue polyol pathway metabolities in streptozotocin-diabetic rats. Diabetologia. 1996; 40:271-81.
51. Hammers HD, Martin S, Federlin K, Geisen K, Bowler M. Aminoguanidine treatment inhibits the development of experimental diabetic retinopathy. Proc Natl Acad Sci U S A. 1991;88:11555-8.
52. Ayepola OR, Brooks NL, Oguntibeju OO. Oxidative Stress and Diabetic Complications: The Role of Antioxidants Vitamins and Flavonoids. Ch. 2. London: IntechOpen; 2014. p. 25-58.
53. Forbes JM, Coughlan MT, Cooper ME. Oxidative stress as a major culprit in kidney disease in diabetes. Diabetes. 2008;57(6):1446-54. doi: 10.2337/db08-0057, PMID 18511445
54. Elmarakby AA, Sullivan JC. Relationship between oxidative stress and inflammatory cytokines in diabetic nephropathy. Cardiovasc Ther. 2012;30(1):49-59.
55. Noh H, Ha H. Reactive oxygen species and oxidative stress. Contrib Nephrol. 2011;170:102-12.
56. Kuhad A, Chopra K. Attenuation of diabetic nephropathy by tocotrienol: Involvement of NFkB signaling pathway. Life Sci. 2009;84(9-10): 296-301. doi: 10.1016/j.lfs.2008.12.014, PMID 19162042
57. Mezzano S, Aros C, Droguett A, Burgos ME, Ardiles L, Flores C, et al. NF-kappaB activation and overexpression of regulated genes in human diabetic nephropathy. Nephrol Dial Transplant. 2004;19(10):2505-12. doi: 10.1093/ndt/gfh207, PMID 15280531
58. Liu W, Zhang X, Liu P, Shen X, Lan T, LiW, et al. Effects of berberine on matrix accumulation and NF-kappa B signal pathway in alloxan-induced diabetic mice with renal injury. Eur J Pharmacol. 2010;1(3):150-5.
59. Brosius FC, Khoury CC, Buller CL, Chen S. Abnormalities in signaling pathways in diabetic nephropathy. Expert Rev Endocrinol Metab. 2010;5(1):51-64. doi: 10.1586/eem.09.70, PMID 20224802
60. Trevisan R, Viberti G. Genetic factors in the and development of diabetic nephropathy. J Lab Clin Med. 1995;126(4):342-9. PMID 7561441
61. Pettitt DJ, Saad MF, Bennett PH, Nelson RG, Knowler WC. Familial predisposition to renal disease in two generations of Pima Indians with type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia. 1990;33(7):438-43. doi: 10.1007/BF00404096, PMID 2401399
62. Imperatore G, Hanson RL, Pettitt DJ, Kobes S, Bennett PH, Knowler WC. Sib-pair linkage analysis for susceptibility genes for microvascular complications among Pima Indians with type 2 diabetes. Pima diabetes genes group. Diabetes. 1998;47(5):821-30. doi: 10.2337/ diabetes.47.5.821, PMID 9588456
63. Vardarli I, Baier LJ, Hanson RL, Akkoyun I, Fischer C, Rohmeiss P, et al. Gene for susceptibility to diabetic nephropathy in type 2 diabetes maps to 18q22.3-23. Kidney Int. 2002;62(6):2176-83. doi: 10.1046/j.1523- 1755.2002.00663.x, PMID 12427143
64. Gall MA, Hougaard P, Borch-Johnsen K, Parving HH. Risk factors for development of incipient and overt diabetic nephropathy in patients with non-insulin dependent diabetes mellitus: Prospective, observational study. BMJ. 1997;314(7083):783-8. doi: 10.1136/bmj.314.7083.783, PMID 9080995
65. Johnson DW, Jones GR, Mathew TH, Ludlow MJ, Chadban SJ, Usherwood T, et al. Chronic kidney disease and measurementof albuminuria or proteinuria: A position statement. Med J Aust. 2012;197(4):224-5.
66. American Diabetes Association. Standards of medical care in diabetes--2014. Diabetes Care. 2014;37 Suppl 1:S14-80. doi: 10.2337/ dc14-S014, PMID 24357209
67. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl. 2024;105(4S):S117-S314. doi: 10.1016/j.kint.2024.02.001
68. Mazzucco G, Bertani T, Fortunato M, Bernardi M, Leutner M, Boldorini R, et al. Different patterns of renal damage in type 2 diabetes mellitus: A multicentric study on 393 biopsies. Am J Kidney Dis. 2002;39(4):713-20. doi: 10.1053/ajkd.2002.31988, PMID 11920336
69. Hull KL, Adenwalla SF, Topham P, Graham-Brown MP. Indications and considerations for kidney biopsy: an overview of clinical considerations for the non-specialist. Clin Med (Lond). 2022 Jan;22(1):34-40. doi: 10.7861/clinmed.2021-0472, PMID 34921054, PMCID PMC8813013
70. Chow FY, Nikolic-Paterson DJ, Ma FY, Ozols E, Rollins BJ, Tesch GH. Monocyte chemoattractant protein-1-induced tissue inflammation is critical for the development of renal injury but not type 2 diabetes in obese db/db mice. Diabetologia. 2007;50(2):471-80. doi: 10.1007/s00125-006-0497-8, PMID 17160673
71. Lim AK, Ma FY, Nikolic-Paterson DJ, Thomas MC, Hurst LA, Tesch GH. Antibody blockade of c-fms suppresses the progression of inflammation and injury in early diabetic nephropathy in obese db/db mice. Diabetologia. 2009;52(8):1669-79. doi: 10.1007/s00125-009- 1399-3, PMID 19466391
72. Furuta T, Saito T, Ootaka T, Soma J, Obara K, Abe K, et al. The role of macrophages in diabetic glomerulosclerosis. Am J Kidney Dis. 1993;21(5):480-5.
73. Fried LF, Emanuele N, Zhang JH, Brophy M, Conner TA, Duckworth W, et al. Combined angiotensin inhibition for the treatment of diabetic nephropathy. N Engl J Med. 2013;369(20):1892-903. doi: 10.1056/ NEJMoa1303154, PMID 24206457
74. Bending JJ, Lobo-Yeo A, Vergani D, Viberti GC. Proteinuria and activated T-lymphocytes in diabetic nephropathy. Diabetes. 1988;37(5):507-11. doi: 10.2337/diab.37.5.507, PMID 3258834
75. Ko GJ, Kang YS, Han SY, Lee MH, Song HK, Han KH, et al. Pioglitazone attenuates diabetic nephropathy through an anti-inflammatory mechanism in type 2 diabetic rats. Nephrol Dial Transplant. 2008;23(9):2750-60. doi: 10.1093/ndt/gfn157, PMID 18388116
76. Ohga S, Shikata K, Yozai K, Okada S, Ogawa D, Usui H, et al. Thiazolidinedione ameliorates renal injury in experimental diabetic rats through anti-inflammatory effects mediated by inhibition of NF-kappaB activation. Am J Physiol Ren Physiol. 2007;292(4):F1141-50.
77. Zhang H, Saha J, Byun J, Schin M, Lorenz M, Kennedy RT, et al. Rosiglitazone reduces renal and plasma markers of oxidative injury and reverses urinary metabolite abnormalities in the amelioration of diabetic nephropathy. Am J Physiol Ren Physiol. 2008;295(4): F1071-81. doi: 10.1152/ajprenal.90208.2008, PMID 18667486
78. Rout P, Jialal I. Diabetic nephropathy. In: Treasure Island, FL: StatPearls Publishing; 2025 Jan 9. StatPearls. p. 2025 Jan. Available from: https:// www.ncbi.nlm.nih.gov/book
79. Li HD, You YK, Shao BY, Wu WF, Wang YF, Guo JB, et al. Roles and crosstalks of macrophages in diabetic nephropathy. Front Immunol. 2022 Nov 2;13:1015142. doi: 10.3389/fimmu.2022.1015142, PMID 36405700, PMCID PMC9666695
80. Kume S, Uzu T, Isshiki K, Koya D. Peroxisome proliferator‐activated receptors in diabetic nephropathy. PPAR Res. 2008;2008(1):879523. doi: 10.1155/2008/879523, PMID 19277201
81. Jones DW, Ferdinand KC, Taler SJ, Johnson HM, Shimbo D, Abdalla M, et al. 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ ASPC/NMA/PCNA/SGIM guideline for the prevention, detection, evaluation and management of high blood pressure in adults: A report of the American college of cardiology/American heart association joint committee on clinical practice guidelines. Hypertension. 2025 Aug 14;82:e212-316. doi:10.1161/HYP.0000000000000249, PMID 40811516
82. Tong PC, Chan SC, Chan WB, Ho KK, Leung GT, Lo SH, et al. Consensus statements from the diabetologists & endocrinologists alliance for the management of people with hypertension and type 2 diabetes mellitus. J Clin Med. 2023 May 11;12(10):3403. doi: 10.3390/ jcm12103403, PMID 37240509, PMCID PMC10219181
83. Diabetes Canada Clinical Practice Guidelines Expert Committee, Houlden RL. Introduction. Can J Diabetes. 2018;42 Suppl 1:S1-5. doi: 10.1016/j.jcjd.2017.10.001, PMID 29650079
84. Santulli G. The 2025 AHA/ACC hypertension guidelines: Implications for cardiovascular and renal risk in patients with diabetes. Cardiovasc Diabetol Endocrinol Rep. 2025;11(1):21. doi: 10.1186/s40842-025- 00239-3, PMID 41013743
85. Kidney Disease Outcomes Quality Initiative. K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis. 2004;43(5 Suppl 1):S1-290.
86. Sung LC, Chiu HW, Yu SM, Tsou LL, Hsu YH, Wu MS, et al. Thiazide diuretics versus loop diuretics in stage 3-5 CKD: Impact on cardiorenal outcomes. Postgrad Med. 2024 Sep;136(7):738-48. doi: 10.1080/00325481.2024.2396796, PMID 39189768
87. Malhotra R, Sharma A, Singh D, Gupta A. Emerging biomarkers in diabetic nephropathy: Recent insights and future perspectives. J Diabetes Res. 2021;2021:9998734.
88. Shashikala P, Nagaraj M, Prasad BG, et al. Biochemical markers for early detection of diabetic nephropathy. Int J Curr Pharm Rev Res. 2024;17(9):251-60.
89. Ka SM, Yeh YC, Huang XR, Chao TK, Hung YJ, Yu CP, et al. Kidney-targeting Smad7 gene transfer inhibits renal TGF-β/MAD homologue (SMAD) and nuclear factor κB (NF-κB) signalling pathways, and improves diabetic nephropathy in mice. Diabetologia. 2012;55(2):509-19. doi: 10.1007/s00125-011-2364-5,PMID 22086159
90. Flaquer M, Franquesa M, Vidal A, Bolaños N, Torras J, Lloberas N, et al. Hepatocyte growth factor gene therapy enhances infiltration of macrophages and may induce kidney repair in db/db mice as a model of diabetes. Diabetologia. 2012;55(7):2059-68. doi: 10.1007/s00125-012- 2535-z, PMID 22460762
91. Li D, Wang N, Zhang L, Hanyu Z, Xueyuan B, Fu B, et al. Mesenchymal stem cells protect podocytes from apoptosis induced by high glucose via secretion of epithelial growth factor. Stem Cell Res Ther. 2013;4(5):103. doi: 10.1186/scrt314, PMID 24004644
92. Zhang Y, Yuen DA, Advani A, Thai K, Advani SL, Kepecs D, et al. Early-outgrowth bone marrow cells attenuate renal injury and dysfunction via an antioxidant effect in a mouse model of type 2 diabetes. Diabetes. 2012;61(8):2114-25. doi: 10.2337/db11-1365, PMID 22596053
Published
How to Cite
Issue
Section
Copyright (c) 2026 Akanksha Dange
This work is licensed under a Creative Commons Attribution 4.0 International License.
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.